Osteoporosis (literally “porous bone”) is a ‘silent killer’ disease that causes more than 8.9 million fractures every year, resulting in an osteoporotic fracture every 3 seconds. Labman, alongside European partners including Universiteit Gent, Fundico and Universitat Rovira i Virgili, are delighted to announce that they will be developing a brand new, high precision device for identifying individuals at risk of the disease.
– Image: MIRACLE, a previous system developed by Labman and other EU partners for the detection of tumour cells – find out more here.
The device, named the PoCOsteo system will employ the very latest technologies and techniques in genomeics and microfluidics to provide a simple to operate point-of-care tool that will seek to revolutionise this critical area in diagnosis. The device can be used anywhere, even in rural areas, meaning anyone at risk of the disease can be identified early, with the aim of vastly reducing the number of people suffering from osteoporosis.
The PoCOsteo device will drastically reduce the cost of testing, as well as the pain and discomfort currently suffered by patients. In an ageing society, the effective diagnosis and treatment of bone diseases is increasingly becoming a high priority. Early detection using the PoCOsteo device will save money, and will allow patients to begin suitable treatment of the disease before complications arise. Over the next four years, Labman and its partners across Europe will be working hard to bring this exciting new device to market.
For a more in-depth description of the project, please click here.